Skip to main content
Serina Therapeutics, Inc. logo

Serina Therapeutics, Inc. — Investor Relations & Filings

Ticker · SER ISIN · US00848H1086 LEI · 5493005PJ4B0GQ36ED85 US Manufacturing
Open in API
Filings indexed 474 across all filing types
Latest filing 2025-01-15 Director's Dealing
Country US United States of America
Listing US SER

About Serina Therapeutics, Inc.

https://serinatherapeutics.com/

Serina Therapeutics, Inc. is a biotechnology company that develops novel therapeutics based on its proprietary POZ platform technology. This platform utilizes advanced polyoxazoline (POZ) polymers to create drug delivery systems for small molecule drugs, aiming to improve their therapeutic properties, safety, and efficacy. The technology is designed for programmable and targeted drug delivery to optimize treatments. The company's development pipeline is focused on addressing unmet medical needs in neurological diseases, including Parkinson's disease, as well as pain, cancer, and inflammation. Serina Therapeutics aims to redefine the standard of care by enhancing the performance of new and existing drug candidates.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2025-01-15 English
FORM 3
Director's Dealing
2025-01-15 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 14, 2025. The key content is the announcement of the appointment of Karen J. Wilson to the Board of Directors and the departure of Steven Mintz from the Board. It includes details about Ms. Wilson's background and committee assignments. There is no financial data or report content; rather, it is an announcement of changes in the company's board of directors. This matches the definition of Board/Management Information (MANG).
2025-01-14 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 6, 2025. It includes an attached investor presentation (Exhibit 99.1) with preliminary, unaudited financial information as of December 31, 2024. The text explicitly states that the attached document is an investor presentation and that the financial information is preliminary and unaudited. The main content is the announcement and furnishing of this investor presentation, not a full financial report or earnings release. The document length is 4425 characters, which is relatively short and consistent with a Form 8-K filing that includes an investor presentation. Therefore, the best classification is Investor Presentation (IP).
2025-01-06 English
8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 23, 2024. It reports the entry into a material definitive agreement (a Stock Purchase Agreement) and the completion of a disposition of assets (sale of a subsidiary). The content focuses on merger and acquisition-related transactions, including details about the merger, asset transfers, and stock purchase agreement. There are no financial statements or quarterly/yearly financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a proxy, earnings release, or governance report. The primary subject is a transaction involving acquisition/disposition of assets and merger-related activities. Therefore, the appropriate classification is M&A Activity (TAR). The document length (7820 characters) supports it being a full report rather than a brief announcement or certification. Confidence is high due to clear merger and acquisition content and SEC Form 8-K context.
2024-12-24 English
Director's Dealing 2024
Director's Dealing
2024-12-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.